Recently, Professor Wang Jianxun, Co-founder, Director, and Chief Scientist of Shenzhen Cell Valley, along with Sun Rui, Head of Marketing, and other colleagues, were invited to revisit Qinghai University Affiliated Hospital. They gathered with Fan Haining, President of the hospital; Su Juan, Vice President; Cui Sen, Academic Director of the Stem Cell and Regenerative Medicine Laboratory; and other departmental experts. Together, they held in-depth discussions and seminars focusing on key issues such as the layout of clinical research projects following the implementation of State Council Decree No. 818 and the construction of the Qinghai Provincial Regional Cell Preparation Center, jointly exploring new pathways for clinical research and industrial implementation of cell therapy technologies in high-altitude regions.

At the beginning of the meeting, relevant officials from Qinghai University Affiliated Hospital elaborated on the current development status, technical achievements, and future plans regarding the hospital's laboratory construction and clinical applications of cell therapy. As a core medical institution in the field of cell therapy in Qinghai Province, the hospital has established a high-standard Stem Cell and Regenerative Medicine Laboratory. It has accumulated rich experience in clinical explorations of cell therapy across multiple fields, including hematological tumors, respiratory diseases, and medical oncology. With strong professional capabilities in its core department teams, the hospital has laid a solid clinical and scientific foundation for conducting high-level clinical research on cell therapy.

Subsequently, Sun Rui, Head of Marketing, introduced Shenzhen Cell Valley's overall achievements in cell therapy technology R&D, clinical translation, and industrial layout. She focused on interpreting the regulatory requirements, implementation pathways, and translational value of cell therapy clinical research projects following the implementation of Decree No. 818. She pointed out that the "Technology Track" regulatory system of Decree No. 818 provides a compliant pathway for personalized and specialized clinical explorations of cell therapy. The hospital's accumulation of expertise in high-altitude medicine highly complements Shenzhen Cell Valley's advantages in technology R&D. By joining hands to layout cell therapy clinical research projects, both parties can not only tap into the potential value of cell therapy for high-altitude diseases but also accumulate regional clinical translation data, helping to create a research paradigm for cell therapy with high-altitude characteristics.

Regarding the construction of the Qinghai Provincial Regional Cell Preparation Center, both sides conducted detailed discussions. Professor Wang Jianxun pointed out that the regional cell preparation center is core infrastructure for clinical research and application of cell therapy; its standardized and regulated construction directly relates to the quality of cell products and the safety of clinical applications. Shenzhen Cell Valley possesses a mature cell preparation technology system and quality management experience. Willing to leverage its own advantages, the company aims to provide technical support, standard formulation, and operational guidance for the construction of the Qinghai Provincial Regional Cell Preparation Center. This will help the center achieve scaled and standardized preparation of clinical-grade cells, meet the core needs of cell therapy clinical research and clinical application within Qinghai Province, and fill the gap in the development of the regional cell preparation industry.

Finally, both sides agreed that the cooperation between Shenzhen Cell Valley and Qinghai University Affiliated Hospital is an important practice in the coordinated development of cross-regional medical technology. It not only aligns with the strategic requirements of the national "Healthy China" and "Healthy Qinghai" initiatives but also fully leverages the resource and technical advantages of both parties to promote the clinical translation and industrial implementation of cell therapy technologies in high-altitude regions.

After the symposium, accompanied by relevant officials from Qinghai University Affiliated Hospital, Professor Wang Jianxun and his delegation visited the hospital's Stem Cell and Regenerative Medicine Laboratory. They conducted on-site inspections of the laboratory's hardware facilities, technical processes, and quality management systems. Both parties exchanged views on-site regarding standardized laboratory operations and optimization of cell preparation technologies, accumulating practical experience for the implementation of subsequent specific cooperation.

This revisit and exchange have laid a solid foundation for deep cooperation between Shenzhen Cell Valley and Qinghai University Affiliated Hospital. In the future, both parties will take the layout of clinical research projects following the implementation of the "818 Policy" and the construction of the Qinghai Provincial Regional Cell Preparation Center as core drivers. They will establish a normalized cooperation and communication mechanism, accelerate the implementation of various cooperative matters, jointly explore new paths and methods for high-altitude characteristic cell therapy, help realize leapfrog development of the cell therapy industry in Qinghai Province, and bring greater health benefits to patients in high-altitude regions.